Scientific publications

Revisiting intracavitary immunotherapy of cancer

May 13, 2022 | Magazine: Clinical Cancer Research

Fernando Aranda  1 , Iñaki Eguren-Santamaria  2 , Angela Bella  1 , Pedro Berraondo  1 , Ignacio Melero  3

Abstract

Ovarian cancer is often limited to the peritoneal cavity in the form of peritoneal carcinomatosis. Peritoneal spreading offers the opportunity for locoregional delivery of combinations of immunotherapy agents, maximizing bioavailability while potentially reducing systemic exposure and side effects.

CITATION  Clin Cancer Res. 2022 May 13;28(10):1993-1995.
doi: 10.1158/1078-0432.CCR-22-0201.

see publication in pubmed

Our authors

Dr. Fernando Aranda Vega Curriculum
Researcher | Principal Investigator Research Group on Immunotherapy Strategies in Peritoneal Carcinomatosis
Imagen Dr. Ignacio Melero Bermejo, Inmunología
Dr. Ignacio Melero Bermejo Curriculum
Senior Researcher | Principal Investigator Immunology and Immunotherapy Research Program
Ángela Bella Carreño
Predoctoral Immunology and Immunotherapy Research Program
Dr. Pedro Berraondo López [SP] Curriculum
Researcher | Principal Investigator Cytokine-Based Therapeutics Research Group
Dr. Iñaki Eguren Santamaría [SP] Curriculum
Predoctoral Immunology and Immunotherapy Research Program